论文部分内容阅读
目的：应用相应单克隆抗体探讨胃癌中雌激素受体（ＥＲ）和孕激素受体ＰＲ表达的临床意义。方法：用ＥＲ、ＰＲ单克隆抗体对１２０例胃癌标本进行免疫组化（ＡＢＣ法）染色。结果：（１）ＥＲ、ＰＲ在１２０例胃癌中阳性表达率分别为３２．５％、３０．８％；两者共同阳性３４例（２８．０％）；（２）ＥＰ、ＰＲ在胃癌Ｂｏｒｍａｎ第４型；胃低分化腺癌；粘液腺癌和有淋巴结转移组其阳性率显著高于其它各组（Ｐ＜０．０１）。而与患者年龄、性别无关（Ｐ＞０．０５）；（３）ＥＲ、ＰＲ共同阳性３４例中，２２例接受化疗加三苯氧胺治疗，１２例单用化疗，随访３年，两者生存率有明显差异（Ｐ＜０．０５）。结论：ＥＰ、ＰＲ阳性表达的胃癌是一种激素依赖性肿瘤，其预后较差，但对接受化疗加内分泌治疗有较好效果，可延长患者生存期。
Objective: To investigate the clinical significance of estrogen receptor (ER) and progesterone receptor (PR) expression in gastric cancer with corresponding monoclonal antibodies. METHODS: Immunohistochemical (ABC) staining of 120 gastric cancer specimens was performed using ER and PR monoclonal antibodies. Results: (1) The positive expression rates of ER and PR in 120 cases of gastric cancer were 32.5% and 30.8%, respectively; 34 cases (28.0%) were positive in both; (2) EP and PR in gastric cancer Borman Type 4; Gastric poorly differentiated adenocarcinoma; Mucinous adenocarcinoma and lymph node metastasis group The positive rate was significantly higher than other groups (P <0.01). However, it was not related to age or gender (P>0.05); (3) Of the 34 patients with common positive ER and PR, 22 patients were treated with chemotherapy and tamoxifen; 12 patients were treated with chemotherapy alone. After 3 years of follow-up, the survival rate was Significant difference (P<0.05). Conclusion: Gastric cancer with positive expression of EP and PR is a hormone-dependent tumor with poor prognosis, but it has good effect on receiving chemotherapy and endocrine therapy, and can prolong survival time.